Clinical Trials
37 trialsVaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Canadian Cancer Trials Group
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy
City of Hope Medical Center
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer
Abramson Cancer Center at Penn Medicine
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
University of Washington
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
Mayo Clinic
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
University of Washington
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Mayo Clinic
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Fred Hutchinson Cancer Center
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
University of California, San Francisco
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Roswell Park Cancer Institute
Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant
City of Hope Medical Center
Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin
National Cancer Institute (NCI)
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
Fred Hutchinson Cancer Center
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
Cancer Trials Ireland
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
National Cancer Institute (NCI)
Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors
National Cancer Institute (NCI)
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
Vanderbilt-Ingram Cancer Center
Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer
NYU Langone Health
Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer
Cytheris SA
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Case Comprehensive Cancer Center
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Cetuximab in Treating Patients With Advanced Solid Tumors
University of California, Davis